Participated · Equity · Jan 2026

Verna develops a software platform that helps companies translate high-level biodiversity and nature-related commitments into actionable, measurable recovery plans. Its product integrates existing environmental data sources and applies AI to optimize planning, on-the-ground implementation, and long-term monitoring of biodiversity outcomes. More than 3,000 users across over 100 organizations currently rely on the platform, underscoring early market traction. Verna’s tools were first built around the UK’s Biodiversity Net Gain framework and are now being extended to additional global nature-recovery standards. Management positions the software as a bridge from risk reporting to verifiable ecological impact, helping businesses improve long-term resilience. With fresh capital, the company intends to expand its AI capabilities and support a wider array of nature-recovery methodologies. The business is headquartered in the United Kingdom and targets organizations with land-related operations or supply chains.

Led · Seed · Nov 2025

Tyten, formerly known as Fixo, builds an AI-powered platform that tackles two persistent bottlenecks in facilities management: help-desk administration and on-site technician support. The software handles repair requests end-to-end, routes jobs to subcontractors, processes technician reports, flags missing information, and issues automatic follow-ups. For technicians, the system offers step-by-step diagnostic and repair guidance, which the company says can shorten job completion times by up to 80%. Tyten claims its tools can save help-desk teams as much as two of every five working days, translating directly into cost savings and improved service levels for property managers and outsourcing providers. More than 400 hours of shadowing technicians and help-desk staff informed the product’s design, giving the team deep insight into real-world workflows. The UK facilities-management market alone is valued at £60 billion, while the global market is estimated at $1.4 trillion, providing a sizable runway for growth. With 70–80% of its new capital earmarked for engineering and product development, Tyten is actively hiring technical talent to accelerate rollout.

Participated · Equity · Jun 2025

3DBioFibR develops scalable biopolymer fibers using a patented dry‑spinning platform that can process over six biopolymers. Its fibers report performance metrics two to three times the strength of natural tissue and are produced at over 3,600× the scale of conventional wet spinning and electrospinning, with improved uniformity and cost‑efficiency. The company has signed paid development agreements and partnerships across tissue engineering, medical devices, defense, cosmetics, and apparel, including several multinational corporations. The recently closed financing will fund ISO 13485 certification, construction of a clean room, and manufacturing scale‑up to meet rising global demand for medical‑grade and performance biomaterials. 3DBioFibR positions itself as a supplier for regulated clinical and therapeutic applications and plans to expand commercial and clinical partnerships. The company is based in Halifax, Nova Scotia. 3D BioFibR develops patented, fully automated collagen-fiber manufacturing technology to produce biofibres that mimic natural materials such as spider silk and collagen. The company is focused on producing recombinant human collagen for the medical research market and launched two products in June: μCollaFibR and CollaFibR, a three-dimensional cell-culture scaffold. To scale production the firm is collaborating with PlantForm Corporation and plans to use PlantForm’s vivoXPRESS plant-based biologics platform rather than mammalian-cell systems. A recent collaborative project funded by Next Generation Manufacturing Canada aims to improve collagen expression scale, increase fiber manufacturing capacity, and validate methods for incorporating recombinant collagen feedstock. 3D BioFibR was founded in 2020 by Sullivan and CSO John Frampton, a biomedical engineering professor at Dalhousie University, and operates with a 12-person team. Financially, the company previously raised $550,000 in 2020 and $700,000 of equity in 2021, and closed an equity and debt round worth $3.52 million in July of this year. 3D BioFibR develops and produces high-value collagen fibers at commercial scale using a proprietary, fully automated dry-spinning process. The company says its process is the only one that produces diameter-controlled collagen fibers at commercial scale and is at least 3,600x faster than competing manufacturing methods. Its collagen fibers are positioned for use in 3D cell culture and tissue engineering, recreating the natural appearance, structure, and function of collagen. 3D BioFibR plans to expand facilities to include a climate-controlled biomanufacturing cleanroom and a new wet lab and cell culture facility to bring its premium collagen fiber products to market. The company is backed by seed financing and receiving government support, including a repayable contribution and NRC IRAP advisory and R&D funding to support development of an automated collagen fiber manufacturing system. Management emphasizes accelerating capacity to meet growing demand from tissue engineers. 3D BioFibR produces naturally sourced, high-value biofibers including collagen (CollaFibR™) and spider silk for use in biomedical engineering, 3D tissue culture, tissue engineering, green textiles, defense, and aerospace. The company uses a proprietary dry-spinning manufacturing process that the team says is faster than current methods and preserves the natural properties of the proteins. Recent messaging emphasizes transition from a lab-based process to an automated production system to deliver consistent, high-quality products at commercial scale. Management plans to scale up and automate manufacturing to be ready for first market sales in the second half of 2022. The company is prioritizing engagement with industry to secure commercial partnerships, with an initial focus on tissue culture and tissue engineering applications. 3D BioFibR was incorporated in July 2020 and is operating from Halifax, Nova Scotia. 3D BioFibR is an advanced biofibre materials company based in Halifax, Nova Scotia, Canada. It manufactures naturally sourced, high-value biofibres including spider silk, collagen and chitosan. The company targets applications across biomedical engineering, green textiles, defense and aerospace. Leadership includes CEO Kevin Sullivan and Chief Scientific Officer Dr. John Frampton. 3D BioFibR plans to use new capital to develop and commercialize its tissue engineering and biomedical device products and to scale up manufacturing of its biofibre platform. The firm raised external funding to support those development and commercialization efforts.

Led · Seed · Oct 2024

Innerlogic builds an AI-driven software suite that replaces traditional employee surveys with conversational, follow-up interactions to surface actionable, solution-focused feedback and generate customized employer reports with cited research and visualizations. The product profiles users via an initial question battery, conducts AI conversations to refine feedback and convert vague comments into action-oriented recommendations, and preserves anonymity to reduce fear of judgment. The company has a 40-client base split roughly evenly between sports teams and businesses, using sports as a beachhead while targeting companies with 500–5,000 employees. Founders Bryce Tully and Mike Bawol—formerly with Canada’s Olympic team—launched the Halifax company after the Tokyo Olympics and landed Own the Podium as their first customer. Innerlogic currently employs eight full-time staff and works with a fractional marketing firm in Nova Scotia. The team plans to use new funding to advance go-to-market efforts, elevate AI capabilities, hone messaging, and grow its digital footprint while scaling the product incrementally.

Led · Seed · Oct 2024

NovaResp develops an artificial intelligence system designed to be compatible with any CPAP machine to predict sleep apnea events and add air pressure proactively rather than reactively. The technology aims to permit lower intervention pressures, improving patient comfort and potentially enabling smaller, lower‑power PAP devices. NovaResp says the system can collect richer user data for analytics and personalized therapy, which it expects will improve adherence and health outcomes. The company is pursuing regulatory approval and commercialization in 2024. NovaResp was founded in 2016 by Dalhousie University biomedical engineer Hamed Hanafi and originally considered manufacturing a physical device but found the algorithm could work without modifying machines. Management has said it may later commercialize its own CPAP machine and explore applications in non‑invasive ventilators and anesthesia machines. NovaResp develops technology to treat sleep apnea and is based in Halifax. The company is advancing its product through clinical trials, and CEO Hamed Hanafi expects the new funding to carry it through completion of those trials. NovaResp raised a $3 million seed extension round to support that work. This extension builds on a $2 million round the company closed in December 2022. The seed extension was led by board member Dr. Neil Smith and included returning investors Concrete Ventures and Invest Nova Scotia.